ANKTIVA® + BCG
BCG-Unresponsive NMIBC CIS
Key Facts
About ImmunityBio
ImmunityBio, founded in 2014 by Dr. Patrick Soon-Shiong, is pioneering immunotherapy 2.0 with a 'triangle offense' approach that simultaneously activates NK cells, T cells, and other immune effectors. The company achieved a major milestone with FDA approval of ANKTIVA® for bladder cancer in April 2024, demonstrating 71% complete response rates and over 90% bladder preservation. With 18 trials in Phase 2 or 3 development and expanding global presence through recent approvals in Europe, Saudi Arabia, and Macau, ImmunityBio is positioned as a leader in the next generation of cancer immunotherapy. The company's platforms address multiple solid tumors and infectious diseases including HIV, representing significant market opportunities beyond their initial bladder cancer indication.
View full company profileAbout ImmunityBio
ImmunityBio, founded in 2014 by Dr. Patrick Soon-Shiong, is pioneering immunotherapy 2.0 with a 'triangle offense' approach that simultaneously activates NK cells, T cells, and other immune effectors. The company achieved a major milestone with FDA approval of ANKTIVA® for bladder cancer in April 2024, demonstrating 71% complete response rates and over 90% bladder preservation. With 18 trials in Phase 2 or 3 development and expanding global presence through recent approvals in Europe, Saudi Arabia, and Macau, ImmunityBio is positioned as a leader in the next generation of cancer immunotherapy. The company's platforms address multiple solid tumors and infectious diseases including HIV, representing significant market opportunities beyond their initial bladder cancer indication.
View full company profile